Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Chief Legal Officer | September 01, 2026 | September 03, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Adm, Leg & BD Off | February 24, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-09-01 | Direct | 7,405 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 7,405 · Balance 7,405 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,837 |
Ending reported balance
After 2021-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-24 · Tax withholding · Disposed 2,416 · Balance 33,865 Row 2 · 2021-02-25 · Sale · Disposed 646 · Balance 33,219 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91). F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-02-25 · Sale · Disposed 1,348 · Balance 31,871 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68). Row 4 · 2021-02-25 · Sale · Disposed 680 · Balance 31,191 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69). Row 5 · 2021-02-25 · Sale · Disposed 354 · Balance 30,837 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 461 | $220.69 | $101,738.09 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,392 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $220.69 (range $220.32 to $220.99). Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $218.93 | $87,572.00 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,853 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $218.93 (range $218.40 to $219.37). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,250 | $122.45 | $520,412.50 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 84 | $205.95 | $17,299.80 |
DisclosureSEC source: 0001209191-19-057142 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,892 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-056709 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,006 Underlying: Common Stock · 4,892 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,892 | $205.50 | $1,005,306.00 |
DisclosureSEC source: 0001209191-19-056709 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,892 | $155.57 | $761,048.44 |
DisclosureSEC source: 0001209191-19-056709 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-055469 · doc4.xml · derivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $201.37 | $120,822.00 |
DisclosureSEC source: 0001209191-19-055469 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $201.37 (range $201.33 to $201.39). Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,730 | $200.20 | $346,346.00 |
DisclosureSEC source: 0001209191-19-055469 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,603 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $200.20 (range $199.81 to $200.52). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-19-055469 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-19-053698 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 01/04/2016. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,250 | $177.80 | $755,650.00 |
DisclosureSEC source: 0001209191-19-053698 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,250 | $122.45 | $520,412.50 |
DisclosureSEC source: 0001209191-19-053698 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · derivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $175.10 | $17,510.00 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,136 | $174.46 | $198,186.56 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,103 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $174.46 (range $174.07 to $174.90). Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 889 | $173.44 | $154,188.16 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,239 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $173.44 (range $172.81 to $173.77). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-044837 · doc4.xml · derivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,980 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,630 | $175.51 | $286,081.30 |
DisclosureSEC source: 0001209191-19-044837 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $175.51 (range $175.07 to $176.04). Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $174.74 | $122,318.00 |
DisclosureSEC source: 0001209191-19-044837 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,633 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $174.74 (range $174.19 to $175.01). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-19-044837 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-19-042070 · doc4.xml · derivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 607 | $175.73 | $106,668.11 |
DisclosureSEC source: 0001209191-19-042070 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $175.73 (range $175.60 to $175.83). Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,518 | $175.09 | $265,786.62 |
DisclosureSEC source: 0001209191-19-042070 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,610 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $175.09 (range $174.55 to $175.53). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-19-042070 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-19-041580 · doc4.xml · derivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 4,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 01/04/2016. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $182.43 | $54,729.00 |
DisclosureSEC source: 0001209191-19-041580 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $182.43 (range $181.78 to $182.88). Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $180.77 | $180,770.00 |
DisclosureSEC source: 0001209191-19-041580 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,303 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $180.77 (range $180.35 to $181.25). Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $179.23 | $89,615.00 |
DisclosureSEC source: 0001209191-19-041580 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,303 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $179.23 (range $178.96 to $179.82). Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,450 | $178.01 | $436,124.50 |
DisclosureSEC source: 0001209191-19-041580 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,803 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $178.01 (range $177.52 to $178.46). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,250 | $122.45 | $520,412.50 |
DisclosureSEC source: 0001209191-19-041580 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed May 6, 2019 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 707 | $173.00 | $122,311.00 |
DisclosureSEC source: 0001209191-19-027688 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,625 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $173.00 (range $172.54 to $173.39). Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 83 | $165.41 | $13,729.03 |
DisclosureSEC source: 0001209191-19-030947 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,329 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-027688 · doc4.xml · derivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,310 Underlying: Common Stock · 2,329 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 622 | $173.72 | $108,053.84 |
DisclosureSEC source: 0001209191-19-027688 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $173.72 (range $173.55 to $173.91). Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $171.71 | $85,855.00 |
DisclosureSEC source: 0001209191-19-027688 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,332 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $171.71 (range $171.35 to $172.16). Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleComon Stock | 500 | $170.33 | $85,165.00 |
DisclosureSEC source: 0001209191-19-027688 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,832 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $170.33 (range $169.96 to $170.63). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,329 | $86.52 | $201,505.08 |
DisclosureSEC source: 0001209191-19-027688 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · derivative · entry 14 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/12/2016. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · derivative · entry 13 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vests in 16 quarterly installments from 1/4/2016. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $184.42 | $73,768.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 12 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $184.42 (range $184.18 to $184.71). Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $183.15 | $18,315.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 11 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,403 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $182.24 | $109,344.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 10 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,503 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $182.24 (range $182.06 to $182.53). Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $181.49 | $108,894.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 9 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,103 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $181.49 (range $180.97 to $181.95). Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 425 | $179.84 | $76,432.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 8 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,703 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $179.84 (range $179.63 to $180.30). Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 660 | $184.44 | $121,730.40 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $184.44 (range $184.18 to $184.71). Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $183.26 | $54,978.00 |
DisclosureSEC source: 0001209191-19-025236 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,663 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $183.26 (range $183.13 to $183.48). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.